Clinical Trial PresentationThe company plans to present data from the wholly-owned casdatifan 100 mg expansion cohort of the Ph 1/1b ARC-20 trial in clear cell renal cell carcinoma at a medical conference.
Investor InterestInvestor interest in the company has been steadily picking up, with most investors focused on the ARC-20 dose expansion read-out with casdatifan, which is expected to be positive.
Stock Price TargetThere is considerable upside for the stock and the price target has been increased from $35 to $46 on the basis of revised product forecasts.